SCHEMBL339441

SCHEMBL339441

CC(C)(C)OC(=O)NCc1cc2nnc(N)n2cc1-c1ccc(Cl)cc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.41
ALDH1A1 P00352 3/20 0.40
HPGD P15428 2/20 0.40
HTT P42858 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
TP53 P04637 3/20 0.40
GLA P06280 1/20 0.40
MAPT P10636 1/20 0.40
XBP1 P17861 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HSD17B10 Q99714 1/20 0.40
CNR1 P21554 3/20 0.37
CNR2 P34972 2/20 0.37
POLB P06746 1/20 0.36
MAPK1 P28482 1/20 0.36
ATM Q13315 1/20 0.36
CA1 P00915 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL339005 0.86 IDO1 (0.40) IDO1ALDH1A1HPGDHTTSMN1; SMN2
SCHEMBL1919688 0.83 ALDH1A1 (0.38) IDO1ALDH1A1HPGDHTTSMN1; SMN2
SCHEMBL338256 0.82 IDO1 (0.40) IDO1ALDH1A1HPGDHTTSMN1; SMN2
SCHEMBL337927 0.81 IDO1 (0.39) IDO1ALDH1A1HPGDHTTSMN1; SMN2
SCHEMBL337909 0.80 IDO1 (0.41) IDO1ALDH1A1HPGDHTTSMN1; SMN2
SCHEMBL1913160 0.79 LMNA (0.41) ALDH1A1HPGDHTTSMN1; SMN2KDM4E
SCHEMBL338980 0.79 IDO1 (0.39) IDO1ALDH1A1HPGDHTTSMN1; SMN2
SCHEMBL339524 0.78 EPHX2 (0.46) IDO1ALDH1A1HPGDHTTSMN1; SMN2
SCHEMBL339213 0.77 IDO1 (0.38) IDO1ALDH1A1HPGDHTTSMN1; SMN2
SCHEMBL339781 0.77 ALDH1A1 (0.38) IDO1ALDH1A1HPGDHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120077787-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2012-03-29 US disclosed
US-20120077787-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2012-03-29 US disclosed
US-8097617-B2 Organic compounds NOVARTIS AG (CH) 2012-01-17 US disclosed
US-8097617-B2 Organic compounds NOVARTIS AG (CH) 2012-01-17 US disclosed
US-8097617-B2 Organic compounds NOVARTIS AG (CH) 2012-01-17 US disclosed
US-20090253689-A1 Organic Compounds NOVARTIS AG (CH) 2009-10-08 US disclosed
US-20090253689-A1 Organic Compounds NOVARTIS AG (CH) 2009-10-08 US disclosed
US-20090253689-A1 Organic Compounds NOVARTIS AG (CH) 2009-10-08 US disclosed
EP-2004643-A1 ORGANIC COMPOUNDS Novartis AG (CH) 2008-12-24 EP disclosed
WO-2007113226-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2007-10-11 WO disclosed
WO-2007113226-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077787-A1 ORGANIC COMPOUNDS OAT, GPR119, OTC IDO1 1621/4885ALDH1A1 480/4885HPGD 934/4885
US-20090253689-A1 Organic Compounds OAT, GPR119, OTC IDO1 1621/4885ALDH1A1 480/4885HPGD 934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.